CD274 and cholangiocarcinoma: Thus, these results suggest that targeted depletion of PD-L1+ dendritic cells would have a potential therapeutic benefit by decreasing primarily the PD-1+ subgroup of effector T cells in all three types of cholangiocarcinoma.